Innohale Therapeutics develops inhaled nitric oxide (iNO) delivery solutions for the treatment of respiratory conditions from many etiologies (including COVID-19) and severe lung infections.

The technology produces iNO from ambient air, which improves treatment accuracy and reduces costs and logistics burden.